Stereotaxis (NYSEAMERICAN:STXS) Director Paul Isaac Acquires 20,000 Shares

Stereotaxis Inc. (NYSEAMERICAN:STXS) Director Paul Isaac purchased 20,000 shares of the firm’s stock in a transaction that occurred on Friday, November 14th. The stock was bought at an average price of $2.24 per share, with a total value of $44,800.00. Following the transaction, the director directly owned 2,786,557 shares in the company, valued at $6,241,887.68. This trade represents a 0.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Stereotaxis Price Performance

NYSEAMERICAN STXS traded up $0.17 on Tuesday, hitting $2.29. 694,472 shares of the company were exchanged, compared to its average volume of 477,972. Stereotaxis Inc. has a twelve month low of $1.54 and a twelve month high of $3.59. The firm has a market capitalization of $208.09 million, a P/E ratio of -7.88 and a beta of 1.65. The company’s 50 day moving average price is $2.92 and its 200-day moving average price is $2.54.

Institutional Trading of Stereotaxis

A number of institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets increased its stake in shares of Stereotaxis by 106.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock worth $36,000 after purchasing an additional 5,910 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Stereotaxis in the first quarter worth about $37,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Stereotaxis in the third quarter worth about $38,000. Moneta Group Investment Advisors LLC bought a new stake in shares of Stereotaxis during the 3rd quarter worth about $43,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Stereotaxis during the 3rd quarter valued at about $54,000. 45.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

STXS has been the subject of a number of research analyst reports. Roth Capital restated a “buy” rating and issued a $4.00 target price on shares of Stereotaxis in a report on Wednesday, November 12th. UBS Group set a $4.00 price objective on Stereotaxis in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Stereotaxis currently has a consensus rating of “Buy” and a consensus price target of $4.00.

Stereotaxis Company Profile

Stereotaxis, Inc designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites.